RG6457 / Roche, Bayer 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RG6457 / Roche, Bayer
NCT06004245: A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Recruiting
1
295
Europe, Canada, US
RO7589831, Pembrolizumab, KEYTRUDA®
Hoffmann-La Roche
Advanced Solid Tumors
12/27
12/27

Download Options